Cargando…

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

Detalles Bibliográficos
Autores principales:	Okuno, Keisuke, Kandimalla, Raju, Mendiola, Marta, Balaguer, Francesc, Bujanda, Luis, Fernandez-Martos, Carlos, Aparicio, Jorge, Feliu, Jaime, Tokunaga, Masanori, Kinugasa, Yusuke, Maurel, Joan, Goel, Ajay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854096/ https://www.ncbi.nlm.nih.gov/pubmed/36670412 http://dx.doi.org/10.1186/s12943-022-01699-2

Ejemplares similares

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Corrigendum: Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2022)

A metastasis‐associated microRNA‐based liquid biopsy signature for risk‐stratification in colorectal cancer: a multicenter cohort study
por: Matsuyama, Takatoshi, et al.
Publicado: (2022)

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2023)

Prognostic Value of Intraoperative Blood Transfusion in Patients with Adenocarcinoma of the Esophagogastric Junction
por: Nakajima, Kei, et al.
Publicado: (2022)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Minimally Invasive Surgery for Colorectal Cancer
por: Yamauchi, Shinichi, et al.
Publicado: (2021)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer
por: Miyazaki, Katsuki, et al.
Publicado: (2023)

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
por: Jongeneel, Gabrielle, et al.
Publicado: (2020)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Robotic-assisted Surgery: Expanding Indication to Colon Cancer in Japan
por: Yamauchi, Shinichi, et al.
Publicado: (2022)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

MicroRNA miR-J1-5p as a potential Biomarker for JC Virus Infection in the Gastrointestinal Tract
por: Link, Alexander, et al.
Publicado: (2014)

Correction to: Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives
por: Tokunaga, Masanori, et al.
Publicado: (2020)

Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives
por: Tokunaga, Masanori, et al.
Publicado: (2019)

Determination of the Minimum Sample Amount for Capillary Electrophoresis-Fourier Transform Mass Spectrometry (CE-FTMS)-Based Metabolomics of Colorectal Cancer Biopsies
por: Sugishita, Tetsuo, et al.
Publicado: (2023)

Comparison of short‐term outcomes between robot‐assisted and laparoscopic rectal surgery for rectal cancer: A propensity score‐matched analysis using the Japanese Nationwide diagnosis procedure combination database
por: Mizoguchi, Masako, et al.
Publicado: (2023)

Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
por: Lee, Dae-Won, et al.
Publicado: (2015)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Distribution of splenic artery lymph nodes and splenic hilar lymph nodes
por: Umebayashi, Yuya, et al.
Publicado: (2023)

Histological study of the structural layers around the esophagus in the lower mediastinum
por: Saito, Toshifumi, et al.
Publicado: (2023)

The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis
por: Wang, Zi-Xian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nb0k9fga1sh94gjmao8hmnvdsg